Results 11 to 20 of about 25,089 (208)

Estudio de las variantes alélicas CYP2C9*2 y CYP2C9*3 en muestras de población mestiza peruana [PDF]

Biomédica: revista del Instituto Nacional de Salud, 2019
Introducción. El citocromo CYP2C9 metaboliza, aproximadamente, el 15 % de los fármacos prescritos. Su gen presenta alelos cuyas frecuencias difieren entre grupos étnicos y poblaciones. Los alelos CYP2C9*2 y CYP2C9*3 dan cuenta de una enzima con actividad
Ángel Tito Alvarado, Ana María Muñoz, Berta Loja, Jessica Michiko Miyasato, Jorge Antonio García, Roberto Andrés Cerro, Luis Abel Quiñones, Nelson Miguel Varela   +7 more
doaj   +2 more sources

CYP2C9*2 and CYP2C9*3 allele variants of CYP2C9 cytochrome gene in St. Petersburg population, and their clinical role in warfarin anticoagulant therapy

Российский кардиологический журнал, 2004
One of the leading anticoagulants in Russia is warfarin. Its pharmacokinetics is determined by structural polymorphisms of CYP2C9 cytochrome gene, metabolizing warfarin.
O. V. Sirotkina, A. S. Ulitina, A. E. Taraskina, M. I. Kadinskaya, T. V. Vavilova, S. N. Pchelina, E. I. Shwartz   +6 more
doaj   +1 more source

CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment

Pharmacogenomics and Personalized Medicine, 2018
Carlos Eduardo Silvado,1 Vera Cristina Terra,1 Carlos Alexandre Twardowschy2 1Comprehensive Epilepsy Program, Hospital de Clinicas, Federal University of Parana (UFPR), Curitiba, Brazil; 2Department of Neurology, Catholic University of Parana (PUCPR ...
Silvado CE, Terra VC, Twardowschy CA
doaj   +1 more source

The Influence of Two CYP2C9 Promoter SNPs on CYP2C9 Expression and Caffeine’s Impact on CYP1A2 [PDF]

, 2013
The R150H polymorphism—the most common in African Americans—is associated with decreased S-warfarin clearance and as a result lower warfarin dose requirements.
David J. Vaynshteyn (7975298)
core   +6 more sources

PharmVar GeneFocus : CYP2C9 [PDF]

, 2021
The Pharmacogene Variation Consortium (PharmVar) catalogues star (*) allele nomenclature for the polymorphic human CYP2C9 gene. Genetic variation within the CYP2C9 gene locus impacts the metabolism or bioactivation of many clinically important drugs ...
Scott, SA, Erica L. Woodahl, Victoria M. Pratt, Larisa H. Cavallari, Del Tredici, Andria L, Michelle Whirl‐Carrillo, Whirl‐Carrillo, Michelle, Karla Claudio‐Campos, Duconge, J, Jorge Duconge, Daly, AK, Duconge, Jorge, Claudio‐Campos, Karla, Pratt, VM, Mia Wadelius, Woodahl, Erica L, Andrea Gaedigk, Scott, Stuart A, Gaedigk, Andrea, Del Tredici, AL, Daly, Ann K., Whirl-Carrillo, M, Rodrigues Botton, Mariana, Katrin Sangkuhl, Claudio-Campos, Karla, Woodahl, EL, Klein, TE, Wadelius, M, Pratt, Victoria M., Ann K. Daly, Sangkuhl, Katrin, Klein, Teri E., Agundez, Jose A G, Daly, Ann K, Claudio-Campos, K, Del Tredici, Andria L., Gaedigk, A, Sangkuhl, K, Wadelius, Mia,, Botton, MR, Andria L. Del Tredici, Klein, Teri E, Mariana Rodrigues Botton, Whirl-Carrillo, Michelle, Cavallari, LH, Woodahl, Erica L., Cavallari, Larisa H, Pratt, Victoria M, Agundez, JAG, Agundez, Jose A.G., Scott, Stuart A., Wadelius, Mia, Stuart A. Scott, Cavallari, Larisa H., Jose A.G. Agundez, Teri E. Klein   +55 more
core   +1 more source

Genetic abnormality of cytochrome-P2C9*3 allele predisposes to epilepsy and phenytoin-induced adverse drug reactions: genotyping findings of cytochrome-alleles in the North Indian population

Future Journal of Pharmaceutical Sciences, 2022
Background This research aims to study the association of genetic polymorphism in genes coding for CYP2C9 and CYP2C19 in phenytoin-induced dose-related toxicity and to assess if the presence of allele CYP2C9*3 plays a role in phenytoin-induced ...
Vivek Kumar Garg, Supriya, Ritu Shree, Ajay Prakash, Aastha Takkar, Madhu Khullar, Biman Saikia, Bikash Medhi, Manish Modi   +8 more
doaj   +1 more source

Pharmacogenetics of sulfonylurea: Presence of CYP2C9*2, CYP2C9*3 and a novel allele, CYP2C9*61, in Type 2 diabetes patients under sulfonylurea therapy

Pakistan Journal of Pharmaceutical Sciences, 2020
CYP2C9 is an important member of the cytochrome P450 gene family involved in the metabolism of 15% of the drugs including an oral antidiabetic agent sulfonylurea.
Sumaira Deen Muhammad, Hazar Khan, Mushtaq Hussain, Tehseen Fatima Zeb, Darshan Kumar, Rahimullah Rahi, Mahayrookh Asif, Akhter Ali Balooch   +7 more
doaj   +1 more source

Pharmacogenomic implications of the differential distribution of CYP2C9 metabolic phenotypes among Latin American populations

Frontiers in Pharmacology, 2023
The CYP2C9 gene encodes the major drug metabolism enzyme CYP2C9. This gene is highly polymorphic, and no-function (CYP2C9*3) plus decreased function (CYP2C9*2, *5, *8 and *11) star alleles (haplotypes) are commonly used to predict CYP2C9 metabolic ...
Guilherme Suarez-Kurtz
doaj   +1 more source

Quantitative assessment of the effect of cytochrome P450 2C9 gene polymorphism and colorectal cancer. [PDF]

PLoS ONE, 2013
CYP2C9 enzyme activity is involved in the metabolism of substances related to colorectal cancer (CRC), and it is functionally linked to a genetic polymorphism.
Yuan Zhao, Yusong Han, Liang Zhang, Yichao Wang, Yushui Ma, Feng Zhang, Da Fu, Xiaofeng Wang   +7 more
doaj   +1 more source

ОСОБЕННОСТИ ВЗАИМОДЕЙСТВИЯ АЗОЛСОДЕРЖАЩИХ СОЕДИНЕНИЙ С ПОЛИМОРФНЫМИ ИЗОФОРМАМИ CYP2C9 [PDF]

, 2018
Azole-containing compounds are often co-administrated with different classes of medications, and are widely used as pesticides in agriculture. Besides the main action, azole-containing compounds can directly affect the human cytochrome P450 system ...
A. M. Tumilovich, A. A. Gilep, Т. А. Сушко, С. А. Усанов, И. В. Гайдукевич, S. A. Usanov, А. А. Гилеп, А. М. Тумилович, I. V. Haidukevich, T. A. Sushko   +9 more
core   +1 more source